Skip to main content

Freeline Therapeutics Holdings PLC (FRLN)

NASDAQ: FRLN · IEX Real-Time Price · USD
3.94 0.09 (2.21%)
Sep 24, 2021 2:23 PM EDT - Market open
Market Cap137.84M
Revenue (ttm)n/a
Net Income (ttm)-137.87M
Shares Out35.80M
EPS (ttm)-5.06
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume59,985
Open3.77
Previous Close3.85
Day's Range3.75 - 3.97
52-Week Range2.92 - 18.88
Betan/a
AnalystsBuy
Price Target14.25 (+262.1%)
Est. Earnings DateNov 10, 2021

About FRLN

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a ...

IndustryBiotechnology
IPO DateAug 7, 2020
Employees236
Stock ExchangeNASDAQ
Ticker SymbolFRLN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for FRLN stock is "Buy." The 12-month stock price forecast is 14.25, which is an increase of 262.13% from the latest price.

Price Target
$14.25
(262.13% upside)
Analyst Consensus: Buy

News

Freeline Appoints Michael J. Parini as Chief Executive Officer and Reports Second Quarter 2021 Financial Results

On track for three programs in the clinic by year end; trial site initiation for FLT180a for Hemophilia B and FLT201 for Gaucher disease Type 1 expected by year end; program for FLT190 for Fabry disease...

1 month ago - GlobeNewsWire

Freeline Provides Executive Leadership Team Update; Company to Provide Corporate Update and Second Quarter 2021 Finan...

Guidance across all programs remains unchanged for expected data and clinical development milestones in 2021 Guidance across all programs remains unchanged for expected data and clinical development mil...

1 month ago - GlobeNewsWire

Freeline Announces Executive Leadership Changes

Appointment of Chief Technical Operations Officer James Bircher continues evolution of leadership team to execute across near- and long-term priorities

2 months ago - GlobeNewsWire

Freeline Doses Second Patient of Phase 1/2 MARVEL-1 Clinical Trial for Fabry Disease

Lowest dose cohort complete and study positioned for dose escalation

3 months ago - GlobeNewsWire

Freeline Reports First Quarter 2021 Financial Results and Recent Business Highlights

FLT190 Phase 1/2 dose-finding study in Fabry disease on track to dose additional patients; Company to present data by year-end

4 months ago - GlobeNewsWire

Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021

LONDON, April 27, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapie...

4 months ago - GlobeNewsWire

Freeline to Participate in Upcoming Investor Conferences in April and May 2021

LONDON, April 21, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated ...

5 months ago - GlobeNewsWire

Freeline Reports Full Year 2020 Financial Results and Business Highlights

Plans to have three AAV gene therapy programs in the clinic by year-end 2021

5 months ago - GlobeNewsWire

Freeline to Present at Upcoming Investor Conferences

LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapie...

5 months ago - GlobeNewsWire

Freeline Presents Data on its Gaucher Disease and Fabry Disease AAV-Based Gene Therapies at the 17th Annual WORLDSymp...

Data demonstrate potential of FLT201 to deliver sustained levels of β-glucocerebrosidase (GCase) variant 85, a proprietary engineered GCase that penetrates target tissues in Gaucher disease

7 months ago - GlobeNewsWire

Freeline Therapeutics To Start FLT180a Dose Confirmation Study In Hemophilia B By 2021 End

Freeline Therapeutics Holdings Plc (NASDAQ: FRLN) has modified its FLT180a clinical development plan for Hemophilia B to address feedback received from the FDA regarding the characterization and compara...

7 months ago - Benzinga

Freeline to Present Data at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorder...

LONDON, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene th...

7 months ago - GlobeNewsWire

Freeline to participate at Conferences during January 2021

LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene th...

8 months ago - GlobeNewsWire

Freeline Reports Updated Data From Phase 1/2 B-AMAZE Trial in Hemophilia B

Updated dose-ranging data demonstrate potential for full normalization of FIX activity

9 months ago - GlobeNewsWire

Freeline to present at the 3rd Annual Evercore ISI Health CONx Conference

LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene th...

10 months ago - GlobeNewsWire

Freeline appoints Mark Baldry as Chief Commercial Officer

LONDON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene th...

10 months ago - GlobeNewsWire